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 Abstract: Background: Breast cancer is one of the leading cancers in women in the Western world. Cancer 
treatment, especially chemotherapy, is often associated with physical and psychosocial side effects.  
Objective: To improve the quality of life and manage side effects, a new integrative mind-body-medicine group 
concept for breast cancer patients receiving chemotherapy was developed and pilot tested.  
Methods: Breast cancer patients participated in a 66 hours mind-body-medicine group program tailored to the 
needs of cancer patients during chemotherapy. The program was integrated into standard care encompassing 
mindfulness training, yoga, moderate exercise, nutrition, complementary self-help strategies, cognitive restruc-
turing, and acupuncture. Quality of life (EORTC QLQ-C30), depression and anxiety (HADS), stress (PSS-10), 
and fatigue (BFI) were assessed before and after the program, as well as satisfaction and safety. Analyses were 
carried out on exploratory basis with paired samples t-tests. 
Results: Fifty-seven female patients, aged 51.3±10.5 years, with breast cancer diagnoses were enrolled. After 
completing the program, global EORTC quality of life was improved (D=9.5; 95%-CI=[2.9|16.1]; p=.005), alt-
hough the EORTC-symptom scales assessing fatigue (D=9.9; 95%-CI=[1|18.8]; p=.030), nausea (D=7.1; 95%-
CI=[0.6|13.6]; p=.031), and dyspnea (D=12.5; 95%-CI=[2.9|22.1]; p=.011) were found to be increased. Stress 
(D=-3.5; 95%-CI=[-5|-2.1]; p=.000), anxiety (D=-3.8; 95%-CI=[-4.9|-2.7]; p=.000) and depression (D=-3.9; 
95%-CI=[-4.9|-2.8]; p=.000) were also found to be significantly reduced. Regarding the severity of (D=0.2; 
95%- CI=[-0.8|0.5]; p=.644) and the impairment due to fatigue (D=0.1; 95%-CI=[-0.8|0.6]; p=.696), no significant 
worsening was observed. Patients were satisfied with the program. No serious adverse events were reported. 
Conclusion: Breast cancer patients benefit from an integrative mind-body-medicine group program during chemo-
therapy regarding the quality of life and psychological symptoms. Randomized controlled trials are warranted. 
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1. INTRODUCTION 
 In 2012, the worldwide incidence of mortality from 27 major 
cancers combined was estimated to account for 14.1 million new 
cases and 8.2 million deaths [1]. Breast cancer has increased in 
prevalence since 1990-2015 [2]. Every year, 1.7 million women 
are newly diagnosed with the most incidences reported from high-
income countries [1]. In Germany, about 71,600 women and nearly 
700 men were diagnosed with breast cancer in 2013 [3]. The rela-
tive 5-year survival rate in Germany was 88% for women [3]. 
While the average number of years of living with a disability has 
improved over the last decades [4], patients’ health-related quality 
of life (HQoL), including physical, psychological, and social di-
mensions, continues to be affected by psychosocial symptoms and 
side effects of cancer treatment [5]. In particular, cancer-related 
fatigue was found to significantly decrease HQoL [6, 7], while 
sleep disturbances, stressful life events, and psychological distress 
contribute to even higher levels of breast-cancer mortality [8-11]. 
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 Several complementary therapies have been proven to amelio-
rate psychological well-being and the HQoL of patients with breast 
cancer [12, 13]. The Clinical Practice Guideline of the Society for 
Integrative Oncology (SIO), which is endorsed by the American 
Society of Clinical Oncology (ASCO) [14], recommends medita-
tion with a grade A evidence to improve anxiety/stress reduction 
and quality of life and Mindfulness Based Stress Reduction 
(MBSR) to enhance depression/mood disturbances. With a Grade 
A evidence, the modality should be offered because there is high 
certainty that the net benefit is substantial [14]. However, hardly 
any hospital in Germany offers the recommended therapies during 
cancer treatment. Despite the fact that about 75% of German pa-
tients with breast cancer are interested in complementary medicine 
(CAM) [15].  
 A core construct of several complementary therapies is mind-
fulness [16]. It involves two components: self-regulation of atten-
tion and adopting a particular orientation toward one’s experience 
in the present moment [17]. The most commonly used mindful-
ness-based interventions are mindfulness-based stress reduction 
(MBSR) and mindfulness-based cognitive therapy (MBCT) [17, 
18]. MBSR is a structured 8-week group program of weekly ses-
sions lasting an average of 2.5 h with an additional silent day re-
treat. Key components of MBSR comprise sitting and walking 
1873-4286/21 © 2021 Bentham Science Publishers
This is an Open Access article  published 
under CC BY 4.0  
https://creativecommons.org/licenses/
by /4.0/legalcode 
Breast Cancer Patients During Chemotherapy Current Pharmaceutical Design, 2021, Vol. 27, No. 8    1113 
meditation, yogic exercises and mindful relaxation techniques. To 
incorporate mindfulness into everyday life, daily home practice is 
recommended and monitored [19]. MBCT combines MBSR tech-
niques with cognitive-behavioral methods such as psychoeduca-
tion, cognitive restructuring, and developing pleasant activities [20, 
21]. In 2017, an updated systematic review and meta-analysis for 
the effectiveness of MBSR and MBCT in women with breast can-
cer were conducted [22], revealing small but significant post-
intervention effects on HQoL, fatigue, sleep, stress, anxiety, and 
depression.  
 Usually, MBSR and comparable mind-body programs are of-
fered to breast cancer patients after completing chemotherapy [23-
25]. In other trials, only some of the patients were on chemothera-
py while participating in the program and subgroup analyses were 
not reported. A reduction of anxiety and depression in breast can-
cer patients and survivors is observed after taking part in these 
interventions [26-28]. Other mind-body therapies like Yoga, Tai 
Chi, and physical exercise are examined during chemotherapy. In a 
recent trial, a yoga program once a week for 12 weeks during 
chemotherapy failed to demonstrate a significant beneficial effect 
on fatigue [29]. Two other recently published studies failed to 
show an effect of yoga on CRF in women with breast cancer dur-
ing (neo)adjuvant treatment [30, 31]. These findings are in contrast 
to the conclusions of a Cochrane Review [12] that “yoga, specifi-
cally, complex yoga interventions incorporating breath control 
and/or meditation beyond physical yoga postures, can be consid-
ered a supportive intervention for improving short term health-
related quality of life, depression, anxiety, fatigue and sleep dis-
turbances in women with recently diagnosed non-metastatic breast 
cancer who are currently undergoing chemotherapy or radiotherapy 
or have completed curative cancer treatment”.  
 So far, no mindfulness program exclusively for cancer patients 
during chemotherapy has been developed. Based on 10 years of 
experience with different integrative mind-body-medicine group 
programs [32, 33], the Department of Complementary and Integra-
tive Medicine and the Breast Unit at the Evang. Kliniken Essen-
Mitte, Germany, have established an innovative, integrative con-
cept that is specially tailored to the particular needs of breast can-
cer patients during chemotherapy. The focus of the mind-body-
medicine group program lies in enhancing the coping abilities as 
well as the treatment of side effects caused by chemotherapy. For 
the latter, acupuncture treatments are implemented within the 
group sessions. The SIO guideline [13] recommends acupuncture 
for selected patients with a Grade C evidence for the reduction of 
hot flushes, pain, fatigue, anxiety, and depression. Grade C evi-
dence recommends selectively offering or providing this service to 
individual patients based on professional judgment and patient 
preferences [14]. Acupressure and electroacupuncture can also be 
considered as an addition to antiemetic drugs to control nausea 
and/or vomiting during chemotherapy (Strength of Evidence Grade 
B: high certainty that the net benefit is moderate or there is moder-
ate certainty that the net benefit is moderate to substantial).  
 The best time to offer psychological/behavioral interventions is 
when stress is high, that is at the time of initial diagnosis and 
treatment [34, 35]. Thus, this observational study aims to examine 
the pilot effects of the developed integrative mind-body-medicine 
group program. 
2. METHODS 
2.1. Design 
 This was a single-arm observational study conducted in 2012 
to 2015 at the Department of Integrative Oncology, Evang. Klin-
iken Essen-Mitte. The study was approved retrospectively by the 
Ethics Committee of the University of Duisburg-Essen (approval 
number 17-7909-BO) and registered retrospectively at ClinicalTri-
als.gov (NCT03868865). The trial was conducted in accordance 
with the declaration of Helsinki and good clinical practice guide-
lines. The writing was supported by Karl und Veronica Carstens-
Stiftung. 
2.2. Patients 
 Patients receiving chemotherapy at the Evang. Kliniken Essen-
Mitte were offered to participate in an integrative mind-body-
medicine group program. Patients were included if they had cura-
tive malignancy (breast cancer of TNM staging I-III), received 
chemotherapy, were at least 18 years old, gave their written in-
formed consent and were willing and physically/mentally able to 
participate in a six hours program eleven times during chemothera-
py. Exclusion criteria included insufficient knowledge of the Ger-
man language, physical or mental disabilities resulting in ineligibil-
ity for participation in the program or filling out the questionnaires. 
2.3. Outcome Measures 
 Outcome measures were assessed before (T0) and after the 
intervention (T1). They encompassed standardized questionnaires 
for quality of life, depression and anxiety, fatigue, perceived stress, 
satisfaction, and adverse events. 
 The European Organization for Research and Treatment of 
Cancer (EORTC) quality of life questionnaire (QLQ-C30) based 
on 30 core items is a cancer-specific multidimensional self-
reporting instrument, which is well validated and used worldwide 
[36, 37]. Besides the global quality of life subscale, this instrument 
assesses five functional domains of quality of life: physical, role, 
emotional, cognitive, and social function. Symptom scales further 
assess fatigue, pain, nausea and vomiting, dyspnea, insomnia, loss 
of appetite, constipation, diarrhea, and financial difficulties. Scores 
of all subscales range from 0 to 100, while a higher score repre-
sents a better level of functioning or a worse amount of symptoms. 
Psychological distress was assessed by the Hospital Anxiety and 
Depression Scale (HADS) to measure the two dimensions, anxiety 
and depression. Scores ranging from 0 to 21 with higher values 
indicate higher distress. Values of ≥8 indicate potential subclinical 
anxiety or depressive disorders [38]. The Brief Fatigue Inventory 
(BFI) has been validated as a short and comprehensive instrument 
to assess the severity of fatigue and fatigue-related impairment in 
cancer patients [39] with a 9-item, 11-point rating scale. Higher 
scores on the BFI correspond to greater severity of fatigue/ 
impairment due to fatigue over the past 24 hours [40].  
 Perceived stress was assessed by the 10-item version of the 
Perceived Stress Scale (PSS) [34, 41], rated for the past month on a 
5-point rating scale. The scale ranged from 0 to 40; a higher total 
score indicated greater stress. 
 Satisfaction was assessed at T1 by 5 questions regarding ful-
filled expectations about the program contents, relevance for coping 
with cancer, social support of the group setting, transferring into 
everyday life, and recommendation of the program. Each question 
could be scored from 1=totally agree to 6=totally disagree.  
 All adverse events that occurred during the study period were 
recorded by the study physician during each integrative mind-
body-medicine group program visit, regardless of their potential 
relation to the study intervention. At T1, patients were also asked 
to report adverse events not previously mentioned. 
2.4. Intervention 
 The integrative mind-body-medicine group program focuses on 
support in coping with the disease, on lifestyle modification [42] 
and on the reduction of chemotherapy-induced side effects. The 
self-contained modules of the program can be followed in an indi-
vidual order to allow the adoption of different chemotherapy re-
gimes. Continued access is possible. Patients can join the program 
eleven times for six hours each visit. They participate in each of 
the eleven modules once (Fig. 1). Usually, the patients join the 
program one or two days ahead of the next chemotherapy cycle. 
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Schedule 
Module 
1 2 3 4 5 6 7 8 9 10 11 
9:00-9:30 Arrival, Meet, Course of The Program, Retrospection 
9:30-10:45 
Manage-
ment of 
side 
effects 
with CM 
Exercise 
during and 
after 
treatment 
Stress-
management 
Nutrition during 
chemotherapy 
CM self-
care strate-
gies 
Coping with 
cancer, 
self-care 
Social 
support 
Relaxation 
techniques 
Management 
of side effects 
with CM 
Mind-
fulness 
Cognitive 
restructu-
ring 
10:45-11:45 Yoga 
11:45-13:45 Lunch (Mediterranean Wholefood Diet) / Physician Group Consultations with Acupuncture 
13:45-14:30 Exercise 
14:30-15:00 PME Body scan 
Breathing-
meditation 
Body scan PME Imagination Body scan 
Breathing-
meditation 
PME 
Breathing-
meditation 
Imagination 
 
Fig. (1). Timetable of the integrative mind-body-medicine group program. Progressive Muscle Relaxation (PME); Complementary Medicine (CM). 
 
For example, if patients receive treatment with epirubicin and cy-
clophosphamide every two weeks, they participate every two 
weeks in the program.  
 The conceptual framework of the program was developed in 
2000 at the Department of Integrative Medicine at Evang. Kliniken 
Essen-Mitte and was published in 2013 [42]. On the one hand, the 
program is based on the MBSR Program developed by Kabat-Zinn 
at the University of Massachusetts [19, 43]. On the other hand, 
elements of the mind-body-medicine cancer program of the Ben-
son-Henry Mind/Body Medical Institute at Harvard Medical 
School are taken into account, which is rooted in psychoneuroen-
docrinology and focuses on relaxation techniques, exercise, cogni-
tive restructuring, diet, and social support [44].  
 Mindfulness-based interventions not only include training in 
the formal practice of mindfulness through meditation and/or 
mindful exercise but also training in the informal practice of mind-
fulness by retaining a mindful state of consciousness during rou-
tine activities in everyday life [19, 45]. The integrative mind-body-
medicine group program is held by health professionals specially 
trained in MBSR, nutrition, physical exercise and psychosocial 
counseling.  
 In addition to elements of the MBSR and Benson programs, 
complementary methods (phytotherapy, compresses and poultices, 
massages, and hydrotherapy) of self-regulation and self-care are 
incorporated that focus on reducing side effects of chemotherapy 
and improving quality of life. During every program visit, a 120 
minutes group medical round with acupuncture treatment provided 
through an integrative oncologist is part of the program. Patients 
can discuss their current medical status, their bothering symptoms 
and adverse events. Individualized recommendations are given and 
targeted acupuncture is provided depending on the reported symp-
toms of each patient. At every visit, blood is drawn first to rule out 
an increased risk of infection through acupuncture treatment in 
case of neutropenia (absolute neutrophil count less than 1000/L). 
Every patient joining the program receives a sea-band at the first 
visit to do acupressure of pericardium 6 in case of nausea and vom-
iting [13], a compact disc with diverse relaxation techniques (for 
example, progressive muscle relaxation as prescribed by Jacobson, 
body scan, breathing exercise, imagination, etc.) and a manual.  
 Each session is complemented by mindful exercise, yoga, or qi 
gong; aerobic exercise, mindful meditation or body scan; and/or 
education on nutrition. Patients are encouraged to practice formal 
mindfulness (with the use of additional material such as manuals 
and compact disc) as well as informal mindfulness at home by 
ensuring a mindful state of consciousness during routine activities 
and to practice aerobic and resistance exercise [46]. 
2.5. Statistical Analysis 
 All analyses were carried out on exploratory basis. Thus, an 
alpha of 0.05 was assumed for all comparisons. Missing values 
were excluded pairwise. The effects were analyzed by paired sam-
ples t-tests and displayed as mean post-pre differences (Δ) with 
95% confidence intervals (CI). All analyses were performed using 
SPSS software (release 22.0, IBM). 
3. RESULTS 
3.1. Patient Flow and Characteristics at Baseline 
 From November 2012 to April 2015, a total of 57 patients re-
ceived the mind-body-medicine program in parallel with their ad-
juvant or neoadjuvant chemotherapy. The patients were female, 
51.1 ± 10.4 years old, and treated for breast cancer stage TNM I 
(29.8%), TNM II (57.9%), and TNM III (12.3%). None of the 57 
patients dropped out during the observation period.  
3.2. Study Effects 
 The results of the analyses are shown in Table 1. After comple-
tion of the program, the patients reported improved global EORTC 
quality of life (Δ=6.9; 95%-CI=[0.8|12.9]; p=.027), while the 
EORTC symptom scales evaluating fatigue (Δ=10.3; 95%-
CI=[1.2|19.4]; p=.027), nausea (Δ=7.7; 95%-CI=[0.7|14.1], p=.031), 
and dyspnea (Δ=12.3; 95%-CI=[2.5|22.2]; p=.015) significantly 
increased and the cognitive functioning scale significantly de-
creased (Δ=9.7; 95%-CI=[1.8|17.6]; p=.017) (Fig. 2). Regarding 
the other EORTC-QLQ-C30 subscales and the intensity of im-
pairment due to fatigue, measured with the BFI, no significant 
changes were observed.  
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Fig. (2). Significant effects measured with the EORTC quality of life questionnaire (QLQ-C30).  European Organization for Research and Treatment of Can-
cer (EORTC); Higher scores represent a better level of functioning in Global Health Status and Cognitive Functioning and a worse amount of symptoms in 
Fatigue, Nausea and Vomiting, and Dyspnoea. (A higher resolution/colour version of this figure is available in the electronic copy of the article). 
 
 
 
Fig. (3). Effects on the PSS, HADS, and BFI. Perceived Stress Scale (PSS)*; Hospital Anxiety and Depression Scale (HADS)*; Brief Fatigue Inventory 
(BFI). Higher values indicate higher stress, anxiety and depression; higher scores on the BFI correspond to greater intensity of fatigue / impairment due to 
fatigue. * means “significant effect”. (A higher resolution/colour version of this figure is available in the electronic copy of the article). 
 
 The perceived stress level (Δ=-3.6; 95%-CI=[-5.2|-2.1]; p=.000), 
anxiety (Δ=-3.8; 95%-CI=[-4.9|-2.6], p=.000), and depression 
(Δ=-3.8; 95%-CI=[-4.8|-2.8]; p=.000) were significantly observed 
to be reduced after the program (Fig. 3).  
3.3. Satisfaction  
 Out of the 57 patients, 96.5% rated that their expectations 
about the program were fulfilled or totally fulfilled, that the topics 
of the program were relevant to cope with cancer, and that the 
group setting was supporting. 91.2% of the patients rated that they 
were able to easily transfer the program contents into everyday life. 
96.5% of the patients would recommend the program to other pa-
tients. Two patients (3.5%) disagreed with all of the statements. In 
addition, three patients who received more than 11 cycles of chem-
otherapy requested a longer program that goes along with every 
chemotherapy cycle. 
 






	


	


	
 	
 !
"#
	
$%&
'
()&

*

*

*
+, -$-.% -$$&, '//%'//#&,#
'
()&
1116    Current Pharmaceutical Design, 2021, Vol. 27, No. 8 Haller et al. 
Table 1. Results of the paired samples t-tests. 
- 
Paired Differences 
Significance  
(2-Tailed) N Baseline Mean Post Mean Mean Difference 
95% Confidence Interval of the Difference 
Lower Upper 
EORTC-QL 51 57.0 63.9 6.9 0.8 12.9 .027 
EORTC-PF 54 79.7 75.8 -3.9 -10.3 2.6 .235 
EORTC-RF 54 55.9 55.6 -0.3 -10.7 10.1 .953 
EORTC-EF 54 55.3 61.6 6.3 -2.6 15.2 .160 
EORTC-CF 55 72.7 63.0 -9.7 -17.6 -1.8 .017 
EORTC-SF 52 63.5 62.2 -1.3 -10.6 8.1 .785 
EORTC-FA 54 43.0 53.3 10.3 1.2 19.4 .027 
EORTC-NV 54 7.4 14.8 7.4 0.7 14.1 .031 
EORTC-PA 54 29.0 25.0 -4.0 -14.6 6.6 .450 
EORTC-DY 54 25.9 38.3 12.3 2.5 22.2 .015 
EORTC-SL 54 42.0 46.3 4.3 -7.4 16.1 .463 
EORTC-AP 53 13.2 16.3 3.1 -6.6 12.9 .520 
EORTC-CO 54 13.6 10.5 -3.1 -14.0 7.8 .574 
EORTC-DI 54 7.4 13.6 6.2 -1.1 13.5 .096 
EORTC-FI 52 17.3 21.1 3.8 -2.2 9.8 .204 
PSS 53 20.1 16.5 -3.6 -5.2 -2.1 .000 
HADS-A 52 9.7 5.9 -3.8 -5.0 -2.6 .000 
HADS-D 52 7.9 4.1 -3.8 -4.8 -2.8 .000 
BFI-INT  50 4.5 4.7 0.2 -0.5 0.8 .557 
BFI-IMP 49 2.8 3.0 0.2 -0.6 0.9 .654 
European Organization for Research and Treatment of Cancer (EORTC); global quality of life (QL); physical function (PF), role function (RF), emotional function (EF), cognitive 
function (CF), and social function (SF); fatigue (FA), nausea and vomiting (NV), pain (PA), dyspnea (DY), insomnia (SL), loss of appetite (AP), constipation (CO), diarrhea (DI), 
and financial difficulties (FI); Perceived Stress Scale (PSS); Hospital Anxiety and Depression Scale (HADS), anxiety (A), depression (D); Brief Fatigue Inventory (BFI), intensity 
of fatigue (INT), fatigue-related impairment (IMP). 
 
3.4. Safety 
 Minor side effects like bruises through acupuncture were re-
ported, but no serious side effects and no infection through the 
acupuncture needle occurred. One patient developed a disk pro-
lapse, which was unrelated to the integrative mind-body-medicine 
group program. 
4. DISCUSSION 
 We evaluated the concept of a new integrative mind-body-
medicine group program for breast cancer patients receiving 
chemotherapy regarding HQoL, fatigue, perceived stress, anxiety, 
and depression. The global quality of life, perceived stress, anxiety 
and depression significantly improved during the participation in 
the program even though the symptoms of nausea, dyspnea and 
fatigue increased significantly. Regarding the severity of and the 
impairment due to fatigue, measured with the BFI, no significant 
changes were observed. The cognitive function decreased signifi-
cantly during chemotherapy, while other functions like physical 
and social rarely changed and emotional function improved.  
 During ongoing chemotherapy, HQol and functional scales 
usually decrease and symptoms like fatigue, insomnia, dyspnea, 
sleep problems, and nausea increase [47-52]. The overall worsen-
ing of physical symptoms correlates with the decrease of the over-
all HQoL [53, 54]. These preliminary findings suggest that partici-
pation in the program might improve HQoL, stress, anxiety and 
depression during ongoing chemotherapy. The HQoL after neoad-
juvant chemotherapy might affect prognosis, so that it seems to be 
highly important to enhance it [53]. Perceived stress shortly after 
diagnosis probably influences the prospective HQoL (especially 
pain and fatigue) one to two years after diagnosis [55, 56]. There-
fore, concepts that address stress early during treatment need to be 
implemented. However, not only stress but also anxiety during 
chemotherapy correlate with the HQoL of women with breast can-
cer. A recent study [54] reported that 44 % of breast cancer pa-
tients after the first cycle of chemotherapy suffered from serious 
or/and intense anxiety with the need to optimize their conventional 
and supportive healthcare. At the end of chemotherapy, an associa-
tion between anxiety and depression and CRF was described by 
another study [57]. In further publications, depression has also 
been found as one of the strongest factors related to CRF [58-61]. 
Patients experience CRF as the most distressing symptom with the 
greatest negative impact on HQoL, with its peak during and shortly 
after chemotherapy [57]. The mind-body therapies assimilated in 
this program are recommended in guidelines to reduce depression, 
anxiety and stress [13]. Additionally, evidence supports the partic-
ipation of breast cancer survivors in Mindfulness Based Stress 
Reduction to reduce CRF [22, 24, 62]. Patients in this trial reported 
a significant increase in CRF after chemotherapy (mean difference 
of 10.3 in the EORTC, effect size 0.38) but the severity of and the 
impairment due to fatigue did not increase significantly (mean 
difference of 0.2 in the BFI each). EORTC and BFI measure dif-
ferent time frames and the clinical relevance remains unclear. In 
addition, the effects might be a result of the reduction of anxiety 
and depression, as associations with CRF are likely. CRF during 
treatment is hypothesized to be caused by the activation of pro-
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inflammatory cytokines [24, 57, 63]. Among breast cancer patients 
undergoing chemotherapy, changes in Interleukin 6 were associat-
ed with changes in fatigue over the course of treatment [64]. Inter-
estingly, mind-body therapies seem to reduce inflammatory mark-
ers and might be a treatment option for CRF [24, 65, 66].  
 In an exercise trial from 2018 [50], the effects of resistance and 
high-intensity interval training to moderate-intensity aerobic and 
high-intensity interval training on usual care in women with breast 
cancer undergoing chemotherapy were compared. The 16 weeks of 
resistance and high-intensity interval training were effective in 
preventing increases in CRF and in reducing symptoms burden for 
patients during chemotherapy. Interestingly, the participants with 
the highest levels of CRF and symptoms and the lowest HQoL 
were those who gained the greatest benefits from the exercise 
training. Maybe in our program, the exercise part needs to be 
strengthened to achieve a better effect concerning CRF during 
chemotherapy. 
 No conclusion can be drawn concerning the effects of the acu-
puncture treatment and complementary self-help strategies in our 
integrative mind-body-medicine group program with regard to 
symptom management. The patients appreciated the acupuncture 
and the self-help recommendations in particular. No serious side 
effects and no infection through acupuncture needles were report-
ed. So far, no reliable data is available concerning the safety of 
acupuncture during neutropenia. In one study, neutropenia was an 
exclusion criterion [67]. In another small feasibility study on ovar-
ian cancer patients during chemotherapy, no serious adverse events 
occurred, but neutropenia was not reported [68].  
 Our findings are only preliminary due to the observational 
design of the study. We are not able to attribute to causation, nor 
are we able to detect which contents of the program led to the ele-
vated HQoL and the decreases in anxiety and depression. Also, we 
did not evaluate the adherence to the recommended exercise and 
relaxation training at home. A further limitation is the small sample 
size.  
 Future research needs to focus on the efficacy and comparative 
effectiveness of the integrative mind-body-medicine group pro-
gram. In a randomized controlled trial, the program could be com-
pared to usual care and to resistance and high-intensity interval 
training or to standard Mindfulness-based Stress Reduction.  
 In the future, we need to implement cost-effective interven-
tions that address the physical and psychological symptoms burden 
during chemotherapy and early in the treatment to improve HQoL 
and maybe even survival in breast cancer patients. 
CONCLUSION 
 Breast cancer patients seem to benefit from an integrative 
mind-body-medicine group program during chemotherapy con-
cerning HQoL and psychological symptoms. Further randomized 
controlled trials are warranted. 
LIST OF ABBREVIATIONS 
ASCO = American Society of Clinical Oncology  
BFI = Brief Fatigue Inventory  
CAM = Complementary and Alternative Medicine  
CI = Confidence Intervals  
CRF = Cancer Related Fatigue  
EORTC = European Organization for Research and Treatment 
of Cancer  
HADS = Hospital Anxiety and Depression Scale  
HQoL = Health Related Quality of Life  
MBCT = Mindfulness-based Cognitive Therapy  
MBSR = Mindfulness Based Stress Reduction  
PSS = Perceived Stress Scale  
QLQ-C30 = Quality of Life Questionnaire  
SIO = Society for Integrative Oncology  
 = Post-pre Differences  
AUTHORS' CONTRIBUTIONS 
 HH analyzed and interpreted the patient data and was a major 
contributor in writing the manuscript. 
 KEC was involved in designing the study and accessing the 
data. 
 SL was involved in designing the study and developing the 
integrative mind-body-medicine group program. 
 SK was involved in recruiting the patients and critically revis-
ing the manuscript. 
 AP was involved in developing the integrative mind-body-
medicine group program and critically revising the manuscript. 
 HC analyzed and interpreted the patient data and critically 
revised the manuscript. 
 GD critically revised the manuscript. 
 PV was involved in designing the study and developing the 
integrative mind-body-medicine group program, and was a major 
contributor in writing the manuscript. 
 All the authors read and approved the final manuscript. 
ETHICS APPROVAL AND CONSENT TO PARTICIPATE 
 The study was approved retrospectively by the Ethics Commit-
tee of the University of Duisburg-Essen (approval number 17-
7909-BO), Germany. 
HUMAN AND ANIMAL RIGHTS 
 No animals were used in this study. Reported experiments on 
humans were in accordance with the ethical standards of the com-
mittee responsible for human experimentation (institutional nation-
al), and with the Helsinki Declaration of 1975, as revised in 2008 
(http://www.wma.net/en/20activities/10ethics/10helsinki/). 
CONSENT FOR PUBLICATION 
 Written and informed consent was obtained from all the pa-
tients. 
AVAILABILITY OF DATA AND MATERIALS 
 The raw-datasets generated and analysed during the current 
study are not publicly available but are available from the corre-
sponding author (Petra Voiss) on reasonable request. 
FUNDING 
 The funding for this study was supported by the Karl und Ve-
ronica Carstens-Stiftung (KVC 0/100/2018). No other funding 
source was given. 
CONFLICT OF INTEREST 
 Petra Voiss reports personal fees for lectures from Novartis, 
Mundipharma, Celgene und Roche outside the submitted work. 
 Sherko Kuemmel reports personal fees from Roche/Genentech, 
Genomic Health, Novartis, Amgen, Celgene, Daiichi Sankyo, Astra 
Zeneca, Somatex, MSD, Pfizer, PFM medical, Lilly, Sonoscape, 
non-financial support from Roche, Daiichi Sankyo, Sonoscape,  
outside the submitted work. 
ACKNOWLEDGEMENTS 
 Declared none. 
1118    Current Pharmaceutical Design, 2021, Vol. 27, No. 8 Haller et al. 
REFERENCES 
[1] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and 
mortality worldwide: sources, methods and major patterns in 
GLOBOCAN 2012. Int J Cancer 2015; 136(5): E359-86. 
http://dx.doi.org/10.1002/ijc.29210 PMID: 25220842 
[2] Global Burden of Disease Study 2013 Collaborators. Global, re-
gional, and national incidence, prevalence, and years lived with 
disability for 301 acute and chronic diseases and injuries in 188 
countries, 1990-2013: a systematic analysis for the Global Burden 
of Disease Study 2013. Lancet 2015; 386(9995): 743-800. 
http://dx.doi.org/10.1016/S0140-6736(15)60692-4 PMID: 
26063472 
[3] Barnes B. Bericht zum Krebsgeschehen in Deutschland 2016. 
Berlin: Robert Koch-Institut 2016. Available at: 
https://edoc.rki.de/handle/176904/3264 
[4] GBD 2015 Disease and Injury Incidence and Prevalence Collabo-
rators. Global, regional, and national incidence, prevalence, and 
years lived with disability for 310 diseases and injuries, 1990-
2015: a systematic analysis for the Global Burden of Disease 
Study 2015. Lancet 2016; 388(10053): 1545-602. 
http://dx.doi.org/10.1016/S0140-6736(16)31678-6 PMID: 
27733282 
[5] Brandão T, Schulz MS, Matos PM. Psychological adjustment after 
breast cancer: a systematic review of longitudinal studies. Psy-
chooncology 2017; 26(7): 917-26. 
http://dx.doi.org/10.1002/pon.4230 PMID: 27440317 
[6] Abrahams HJG, Gielissen MFM, Schmits IC, Verhagen 
CAHHVM, Rovers MM, Knoop H. Risk factors, prevalence, and 
course of severe fatigue after breast cancer treatment: a meta-
analysis involving 12 327 breast cancer survivors. Ann Oncol 
2016; 27(6): 965-74. 
http://dx.doi.org/10.1093/annonc/mdw099 PMID: 26940687 
[7] Alcântara-Silva TR, Freitas-Junior R, Freitas NM, Machado GD. 
Fatigue related to radiotherapy for breast and/or gynaecological 
cancer: a systematic review. J Clin Nurs 2013; 22(19-20): 2679-
86. 
http://dx.doi.org/10.1111/jocn.12236 PMID: 23651041 
[8] Trudel-Fitzgerald C, Zhou ES, Poole EM, et al. Sleep and survival 
among women with breast cancer: 30 years of follow-up within 
the Nurses’ Health Study. Br J Cancer 2017; 116(9): 1239-46. 
http://dx.doi.org/10.1038/bjc.2017.85 PMID: 28359077 
[9] Chida Y, Hamer M, Wardle J, Steptoe A. Do stress-related psy-
chosocial factors contribute to cancer incidence and survival? Nat 
Clin Pract Oncol 2008; 5(8): 466-75. 
http://dx.doi.org/10.1038/ncponc1134 PMID: 18493231 
[10] Lin X, Chen W, Wei F, Ying M, Wei W, Xie X. Night-shift work 
increases morbidity of breast cancer and all-cause mortality: a me-
ta-analysis of 16 prospective cohort studies. Sleep Med 2015; 
16(11): 1381-7. 
http://dx.doi.org/10.1016/j.sleep.2015.02.543 PMID: 26498240 
[11] Suppli NP, Johansen C, Kessing LV, et al. Survival After Early-
Stage Breast Cancer of Women Previously Treated for Depres-
sion: A Nationwide Danish Cohort Study. J Clin Oncol 2017; 
35(3): 334-42. 
http://dx.doi.org/10.1200/JCO.2016.68.8358 PMID: 28095267 
[12] Cramer H, Lauche R, Klose P, Lange S, Langhorst J, Dobos GJ. 
Yoga for improving health-related quality of life, mental health 
and cancer-related symptoms in women diagnosed with breast 
cancer. Cochrane Database Syst Rev 2017; 1: CD010802. 
http://dx.doi.org/10.1002/14651858.CD010802.pub2 PMID: 
28045199 
[13] Greenlee H, DuPont-Reyes MJ, Balneaves LG, et al. Clinical 
practice guidelines on the evidence-based use of integrative thera-
pies during and after breast cancer treatment. CA Cancer J Clin 
2017; 67(3): 194-232. 
http://dx.doi.org/10.3322/caac.21397 PMID: 28436999 
[14] Lyman GH, Greenlee H, Bohlke K, et al. Integrative Therapies 
During and After Breast Cancer Treatment: ASCO Endorsement 
of the SIO Clinical Practice Guideline. J Clin Oncol 2018; 36(25): 
2647-55. 
http://dx.doi.org/10.1200/JCO.2018.79.2721 PMID: 29889605 
[15] Fremd C, Hack CC, Schneeweiss A, et al. Use of complementary 
and integrative medicine among German breast cancer patients: 
predictors and implications for patient care within the PRAE-
GNANT study network. Arch Gynecol Obstet 2017; 295(5): 1239-
45. 
http://dx.doi.org/10.1007/s00404-017-4348-2 PMID: 28331996 
[16] Ludwig DS, Kabat-Zinn J. Mindfulness in medicine. JAMA 2008; 
300(11): 1350-2. 
http://dx.doi.org/10.1001/jama.300.11.1350 PMID: 18799450 
[17] Bishop SR. Mindfulness: a proposed operational definition. Clin 
Psychol Sci Pract 2004; 11: 230-41. 
http://dx.doi.org/10.1093/clipsy.bph077 
[18] Baer RA. Mindfulness training as a clinical intervention: A con-
ceptual and empirical review. Clin Psychol Sci Pract 2003; 10: 
125-43. 
http://dx.doi.org/10.1093/clipsy.bpg015 
[19] Kabat-Zinn J. Full catastrophe living: using the wisdom of your 
body and mind to face stress, pain, and illness. New York: Delta 
Trade Paperback/Bantam Dell 1990. 
[20] Teasdale JD, Segal ZV, Williams JM, Ridgeway VA, Soulsby JM, 
Lau MA. Prevention of relapse/recurrence in major depression by 
mindfulness-based cognitive therapy. J Consult Clin Psychol 
2000; 68(4): 615-23. 
http://dx.doi.org/10.1037/0022-006X.68.4.615 PMID: 10965637 
[21] Crane R. Mindfulness-based cognitive therapy: distinctive fea-
tures. New York, NY: Routledge/Taylor & Francis Group 2009. 
[22] Haller H, Winkler MM, Klose P, Dobos G, Kümmel S, Cramer H. 
Mindfulness-based interventions for women with breast cancer: an 
updated systematic review and meta-analysis. Acta Oncol 2017; 
56(12): 1665-76. 
http://dx.doi.org/10.1080/0284186X.2017.1342862 PMID: 
28686520 
[23] Hoffman CJ, Ersser SJ, Hopkinson JB, Nicholls PG, Harrington 
JE, Thomas PW. Effectiveness of mindfulness-based stress reduc-
tion in mood, breast- and endocrine-related quality of life, and 
well-being in stage 0 to III breast cancer: a randomized, controlled 
trial. J Clin Oncol 2012; 30(12): 1335-42. 
http://dx.doi.org/10.1200/JCO.2010.34.0331 PMID: 22430268 
[24] Lengacher CA. A Large Randomized Trial: Effects of Mindful-
ness-Based Stress Reduction (MBSR) for Breast Cancer (BC) 
Survivors on Salivary Cortisol and IL-6. Biol Res Nurs 2019; 
21(1): 39-49. 
PMID: 30079756 
[25] Reich RR, Lengacher CA, Alinat CB, et al. Mindfulness-Based 
Stress Reduction in Post-treatment Breast Cancer Patients: Imme-
diate and Sustained Effects Across Multiple Symptom Clusters. J 
Pain Symptom Manage 2017; 53(1): 85-95. 
http://dx.doi.org/10.1016/j.jpainsymman.2016.08.005 PMID: 
27720794 
[26] Henderson VP, Clemow L, Massion AO, Hurley TG, Druker S, 
Hébert JR. The effects of mindfulness-based stress reduction on 
psychosocial outcomes and quality of life in early-stage breast 
cancer patients: a randomized trial. Breast Cancer Res Treat 2012; 
131(1): 99-109. 
http://dx.doi.org/10.1007/s10549-011-1738-1 PMID: 21901389 
[27] Würtzen H, Dalton SO, Elsass P, et al. Mindfulness significantly 
reduces self-reported levels of anxiety and depression: results of a 
randomised controlled trial among 336 Danish women treated for 
stage I-III breast cancer. Eur J Cancer 2013; 49(6): 1365-73. 
http://dx.doi.org/10.1016/j.ejca.2012.10.030 PMID: 23265707 
[28] Jeitler M, Jaspers J, von Scheidt C, et al. Mind-body medicine and 
lifestyle modification in supportive cancer care: A cohort study on 
a day care clinic program for cancer patients. Psychooncology 
2017; 26(12): 2127-34. 
http://dx.doi.org/10.1002/pon.4433 PMID: 28370730 
[29] Jong MC, Boers I, Schouten van der Velden AP, et al. A Random-
ized Study of Yoga for Fatigue and Quality of Life in Women with 
Breast Cancer Undergoing (Neo) Adjuvant Chemotherapy. J Al-
tern Complement Med 2018; 24(9-10): 942-53. 
http://dx.doi.org/10.1089/acm.2018.0191 PMID: 30247961 
[30] Lötzke D, Wiedemann F, Rodrigues Recchia D, et al. Iyengar-
Yoga Compared to Exercise as a Therapeutic Intervention during 
(Neo)adjuvant Therapy in Women with Stage I-III Breast Cancer: 
Health-Related Quality of Life, Mindfulness, Spirituality, Life Sat-
isfaction, and Cancer-Related Fatigue. Evid Based Complement 
Alternat Med 2016; 2016: 5931816. 
Breast Cancer Patients During Chemotherapy Current Pharmaceutical Design, 2021, Vol. 27, No. 8    1119 
http://dx.doi.org/10.1155/2016/5931816 PMID: 27019663 
[31] Chaoul A, Milbury K, Spelman A, et al. Randomized trial of Ti-
betan yoga in patients with breast cancer undergoing chemothera-
py. Cancer 2018; 124(1): 36-45. 
http://dx.doi.org/10.1002/cncr.30938 PMID: 28940301 
[32] Spahn G, Choi KE, Kennemann C, et al. Can a multimodal mind-
body program enhance the treatment effects of physical activity in 
breast cancer survivors with chronic tumor-associated fatigue? A 
randomized controlled trial. Integr Cancer Ther 2013; 12(4): 291-
300. 
http://dx.doi.org/10.1177/1534735413492727 PMID: 23766391 
[33] Dobos G, Overhamm T, Büssing A, et al. Integrating mindfulness 
in supportive cancer care: a cohort study on a mindfulness-based 
day care clinic for cancer survivors. Support Care Cancer 2015; 
23(10): 2945-55. 
http://dx.doi.org/10.1007/s00520-015-2660-6 PMID: 25711654 
[34] Golden-Kreutz DM, Browne MW, Frierson GM, Andersen BL. 
Assessing stress in cancer patients: a second-order factor analysis 
model for the Perceived Stress Scale. Assessment 2004; 11(3): 
216-23. 
http://dx.doi.org/10.1177/1073191104267398 PMID: 15358877 
[35] Golden-Kreutz DM, Thornton LM, Wells-Di Gregorio S, et al. 
Traumatic stress, perceived global stress, and life events: prospec-
tively predicting quality of life in breast cancer patients. Health 
Psychol 2005; 24(3): 288-96. 
http://dx.doi.org/10.1037/0278-6133.24.3.288 PMID: 15898865 
[36] Montazeri A. Health-related quality of life in breast cancer pa-
tients: a bibliographic review of the literature from 1974 to 2007. J 
Exp Clin Cancer Res 2008; 27: 32. 
http://dx.doi.org/10.1186/1756-9966-27-32 PMID: 18759983 
[37] Aaronson NK, Ahmedzai S, Bergman B, et al. The European 
Organization for Research and Treatment of Cancer QLQ-C30: a 
quality-of-life instrument for use in international clinical trials in 
oncology. J Natl Cancer Inst 1993; 85(5): 365-76. 
http://dx.doi.org/10.1093/jnci/85.5.365 PMID: 8433390 
[38] Zigmond AS, Snaith RP. The hospital anxiety and depression 
scale. Acta Psychiatr Scand 1983; 67(6): 361-70. 
http://dx.doi.org/10.1111/j.1600-0447.1983.tb09716.x PMID: 
6880820 
[39] Radbruch L, Sabatowski R, Elsner F, Everts J, Mendoza T, Clee-
land C. Validation of the German version of the brief fatigue in-
ventory. J Pain Symptom Manage 2003; 25(5): 449-58. 
http://dx.doi.org/10.1016/S0885-3924(03)00073-3 PMID: 
12727043 
[40] Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment 
of fatigue severity in cancer patients: use of the Brief Fatigue In-
ventory. Cancer 1999; 85(5): 1186-96. 
http://dx.doi.org/10.1002/(SICI)1097-
0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N PMID: 
10091805 
[41] Cohen S, Janicki-Deverts D. Who’s Stressed? Distributions of 
Psychological Stress in the United States in Probability Samples 
from 1983, 2006, and 20091. J Appl Soc Psychol 2012; 42(6): 
1320-34. 
http://dx.doi.org/10.1111/j.1559-1816.2012.00900.x 
[42] Paul A, Cramer H, Lauche R, Altner N, Langhorst J, Dobos GJ. 
An oncology mind-body medicine day care clinic: concept and 
case presentation. Integr Cancer Ther 2013; 12(6): 503-7. 
http://dx.doi.org/10.1177/1534735412473639 PMID: 23329568 
[43] Kabat-Zinn J. An outpatient program in behavioral medicine for 
chronic pain patients based on the practice of mindfulness medita-
tion: theoretical considerations and preliminary results. Gen Hosp 
Psychiatry 1982; 4(1): 33-47. 
http://dx.doi.org/10.1016/0163-8343(82)90026-3 PMID: 7042457 
[44] Benson H, Stuart M. The wellness book Mind-body medicine. 
New York, NY: Fireside 1999. 
[45] Shapiro SL, Carlson LE, Astin JA, Freedman B. Mechanisms of 
mindfulness. J Clin Psychol 2006; 62(3): 373-86. 
http://dx.doi.org/10.1002/jclp.20237 PMID: 16385481 
[46] Cormie P, Atkinson M, Bucci L, et al. Clinical Oncology Society 
of Australia position statement on exercise in cancer care. Med J 
Aust 2018; 209(4): 184-7. 
http://dx.doi.org/10.5694/mja18.00199 PMID: 29719196 
[47] Ancoli-Israel S, Liu L, Rissling M, et al. Sleep, fatigue, depres-
sion, and circadian activity rhythms in women with breast cancer 
before and after treatment: a 1-year longitudinal study. Support 
Care Cancer 2014; 22(9): 2535-45. 
http://dx.doi.org/10.1007/s00520-014-2204-5 PMID: 24733634 
[48] Grassi L, Berardi MA, Ruffilli F, et al. IOR-IRST Psycho-
Oncology and UniFE Psychiatry Co-Authors. Role of psychoso-
cial variables on chemotherapy-induced nausea and vomiting and 
health-related quality of life among cancer patients: a European 
study. Psychother Psychosom 2015; 84(6): 339-47. 
http://dx.doi.org/10.1159/000431256 PMID: 26402426 
[49] Alawadi SA, Ohaeri JU. Health - related quality of life of Kuwaiti 
women with breast cancer: a comparative study using the EORTC 
Quality of Life Questionnaire. BMC Cancer 2009; 9: 222. 
http://dx.doi.org/10.1186/1471-2407-9-222 PMID: 19586536 
[50] Mijwel S, Backman M, Bolam KA, et al. Adding high-intensity 
interval training to conventional training modalities: optimizing 
health-related outcomes during chemotherapy for breast cancer: 
the OptiTrain randomized controlled trial. Breast Cancer Res Treat 
2018; 168(1): 79-93. 
http://dx.doi.org/10.1007/s10549-017-4571-3 PMID: 29139007 
[51] Sultan A, Choudhary V, Parganiha A. Worsening of rest-activity 
circadian rhythm and quality of life in female breast cancer pa-
tients along progression of chemotherapy cycles. Chronobiol Int 
2017; 34(5): 609-23. 
http://dx.doi.org/10.1080/07420528.2017.1286501 PMID: 
28276853 
[52] Groenvold M. Health-related quality of life in early breast cancer. 
Dan Med Bull 2010; 57(9): B4184. 
PMID: 20816024 
[53] Takada K, Kashiwagi S, Goto W, et al. Novel evaluation scale for 
QOL (QOL-ACD-BP) in preoperative chemotherapy for breast 
cancer. J Cancer Res Clin Oncol 2018; 144(8): 1547-59. 
http://dx.doi.org/10.1007/s00432-018-2670-0 PMID: 29779135 
[54] Charalambous A, Kaite CP, Charalambous M, Tistsi T, Kouta C. 
The effects on anxiety and quality of life of breast cancer patients 
following completion of the first cycle of chemotherapy. SAGE 
Open Med 2017; 5: 2050312117717507. 
http://dx.doi.org/10.1177/2050312117717507 PMID: 28694967 
[55] Härtl K, Engel J, Herschbach P, Reinecker H, Sommer H, Friese 
K. Personality traits and psychosocial stress: quality of life over 2 
years following breast cancer diagnosis and psychological impact 
factors. Psychooncology 2010; 19(2): 160-9. 
http://dx.doi.org/10.1002/pon.1536 PMID: 19189279 
[56] Harris LN, Bauer MR, Wiley JF, et al. Chronic and episodic stress 
predict physical symptom bother following breast cancer diagno-
sis. J Behav Med 2017; 40(6): 875-85. 
http://dx.doi.org/10.1007/s10865-017-9855-x PMID: 28528393 
[57] Fabi A, Falcicchio C, Giannarelli D, Maggi G, Cognetti F, 
Pugliese P. The course of cancer related fatigue up to ten years in 
early breast cancer patients: What impact in clinical practice? 
Breast 2017; 34: 44-52. 
http://dx.doi.org/10.1016/j.breast.2017.04.012 PMID: 28500901 
[58] Servaes P, Gielissen MF, Verhagen S, Bleijenberg G. The course 
of severe fatigue in disease-free breast cancer patients: a longitu-
dinal study. Psychooncology 2007; 16(9): 787-95. 
http://dx.doi.org/10.1002/pon.1120 PMID: 17086555 
[59] Servaes P, Verhagen CA, Bleijenberg G. Relations between fa-
tigue, neuropsychological functioning, and physical activity after 
treatment for breast carcinoma: daily self-report and objective be-
havior. Cancer 2002; 95(9): 2017-26. 
http://dx.doi.org/10.1002/cncr.10891 PMID: 12404297 
[60] Nieboer P, Buijs C, Rodenhuis S, et al. Fatigue and relating fac-
tors in high-risk breast cancer patients treated with adjuvant stand-
ard or high-dose chemotherapy: a longitudinal study. J Clin Oncol 
2005; 23(33): 8296-304. 
http://dx.doi.org/10.1200/JCO.2005.10.167 PMID: 16219926 
[61] Bower JE, Wiley J, Petersen L, Irwin MR, Cole SW, Ganz PA. 
Fatigue after breast cancer treatment: Biobehavioral predictors of 
fatigue trajectories. Health Psychol 2018; 37(11): 1025-34. 
http://dx.doi.org/10.1037/hea0000652 PMID: 30321021 
[62] Zhang Q, Zhao H, Zheng Y. Effectiveness of mindfulness-based 
stress reduction (MBSR) on symptom variables and health-related 
1120    Current Pharmaceutical Design, 2021, Vol. 27, No. 8 Haller et al. 
quality of life in breast cancer patients-a systematic review and 
meta-analysis. Support Care Cancer 2018. 
http://dx.doi.org/10.1111/ecc.12632 PMID: 30488223 
[63] Bower JE, Ganz PA, Irwin MR, Kwan L, Breen EC, Cole SW. 
Inflammation and behavioral symptoms after breast cancer treat-
ment: do fatigue, depression, and sleep disturbance share a com-
mon underlying mechanism? J Clin Oncol 2011; 29(26): 3517-22. 
http://dx.doi.org/10.1200/JCO.2011.36.1154 PMID: 21825266 
[64] Liu L, Mills PJ, Rissling M, et al. Fatigue and sleep quality are 
associated with changes in inflammatory markers in breast cancer 
patients undergoing chemotherapy. Brain Behav Immun 2012; 
26(5): 706-13. 
http://dx.doi.org/10.1016/j.bbi.2012.02.001 PMID: 22406004 
[65] Bower JE, Irwin MR. Mind-body therapies and control of inflam-
matory biology: A descriptive review. Brain Behav Immun 2016; 
51: 1-11. 
http://dx.doi.org/10.1016/j.bbi.2015.06.012 PMID: 26116436 
[66] Bower JE. Cancer-related fatigue-mechanisms, risk factors, and 
treatments. Nat Rev Clin Oncol 2014; 11(10): 597-609. 
http://dx.doi.org/10.1038/nrclinonc.2014.127 PMID: 25113839 
[67] Pais I, Correia N, Pimentel I, et al. Effects of acupuncture on 
leucopenia, neutropenia, NK, and B cells in cancer patients: a ran-
domized pilot study. Evid Based Complement Alternat Med 2014; 
2014: 217397. 
http://dx.doi.org/10.1155/2014/217397 PMID: 25152759 
[68] Lu W, Matulonis UA, Dunn JE, et al. The Feasibility and Effects 
of Acupuncture on Quality of Life Scores During Chemotherapy 
in Ovarian Cancer: Results from a Pilot, Randomized Sham-
Controlled Trial. Med Acupunct 2012; 24(4): 233-40. 
http://dx.doi.org/10.1089/acu.2012.0904 PMID: 24761165 
 
 
 
 
 
